Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy.

Abstract

To examine diagnostic reference levels (DRL) and achievable doses (AD) of image-guided and size-specific dose estimates (SSDE) and organ and effective doses of CT-guided intrathecal nusinersen administration to adult patients with spinal muscular atrophy (SMA). This study involved a total of 60 image-guided intrathecal nusinersen treatments between August 2017 and June 2018. Patient cohort comprised 14 adult patients with the following SMA types: type 2 (n = 9) and type 3 (n = 5) with a mean age of 33.6years (age range 25-57years). DRL, AD, SSDE, organ, and effective doses were assessed with a dose-monitoring program based on the Monte Carlo simulation techniques. DRL and AD for computed tomography are summarised as follows: in terms of CT-dose index (CTDIvol), DRL 56.4mGy and AD 36.7mGy; in terms of dose-length product (DLP), DRL 233.1mGycm and AD 120.1mGycm. DRL and AD for fluoroscopic guidance were distributed as follows: in terms of dose-area product (DAP), DRL 239.1μGym2 and AD 135.2mGycm2. Mean SSDE was 9.2mGy. Mean effective dose of the CT-guided injections was 2.5mSv (median 2.0mSv, IQR 1.3-3.2mSv). Highest organ doses in the primary beam of radiation were the small intestine 12.9mSv, large intestine 9.5mSv, and ovaries 3.6mSv. Radiation exposure of SMA patients measured as DRLs is generally not higher compared with patients without SMA despite severe anatomical hazards. Dose monitoring data may allow clinicians to stratify radiation risk, identify organs at risk, and adopt measures for specific radiation dose reduction.